Laurence Katznelson1. 1. Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305-5821, USA. atznelson@stanford.edu
Abstract
BACKGROUND: Acromegaly is an insidious disease due to growth hormone (GH) hypersecretion from a pituitary adenoma, and is associated with multiple comorbidities and risk of premature mortality. OBJECTIVES: To review the therapeutic goals and options for acromegaly. METHODS: Literature review. RESULTS/ CONCLUSION: Surgery is the mainstay of therapy, but a role for primary medical therapy using somatostatin analogs is described as well. Somatostatin analogs are the mainstay for medical therapy, largely in an adjuvant setting. The GH receptor antagonist is also used and may be considered in addition to the somatostatin analogs, or as second line therapy. Based on these multiple modalities of therapy, it should be possible to achieve biochemical control in almost all patients.
BACKGROUND:Acromegaly is an insidious disease due to growth hormone (GH) hypersecretion from a pituitary adenoma, and is associated with multiple comorbidities and risk of premature mortality. OBJECTIVES: To review the therapeutic goals and options for acromegaly. METHODS: Literature review. RESULTS/ CONCLUSION: Surgery is the mainstay of therapy, but a role for primary medical therapy using somatostatin analogs is described as well. Somatostatin analogs are the mainstay for medical therapy, largely in an adjuvant setting. The GH receptor antagonist is also used and may be considered in addition to the somatostatin analogs, or as second line therapy. Based on these multiple modalities of therapy, it should be possible to achieve biochemical control in almost all patients.
Authors: Lucio Vilar; Monalisa F Azevedo; Luciana Ansaneli Naves; Luiz Augusto Casulari; José Luciano Albuquerque; Renan M Montenegro; Renan M Montenegro; Patricia Figueiredo; Gilvan C Nascimento; Manuel S Faria Journal: Pituitary Date: 2011-06 Impact factor: 4.107